Monomeric Peptide Multi-agonist Targeting the GLP1 Receptor and NPY Receptors

Robert Patrick Doyle (Inventor), Brandon T. Milliken (Inventor)

Research output: Patent


A series of chimeric peptides that provide a mechanism for obesity treatment concomitant with T2DM in the form of dual agonism of the anorectic neuropeptide Y-receptor (Y2-R) and the glucoregulatory receptor GLP1-R. Preliminary results show that, dependent on the selected peptide, once-daily administration suppress FI in male and female rats can be reduced to 12-65% compared to baseline conditions before treatment, dependent on dose and age of animals, and glucose tolerance can be improved as well. Peptides also demonstrated Yl -receptor agonism, conferring protection on beta-islet cells against inflammatory damage. The peptides were designed by targeting serial anorectic pathways simultaneously and are promising candidates for modulating FI and glucoregulation in an efficacious and safe way.
Original languageEnglish (US)
Priority date4/1/19
Filing date4/1/20
StatePublished - Aug 10 2020


Dive into the research topics of 'Monomeric Peptide Multi-agonist Targeting the GLP1 Receptor and NPY Receptors'. Together they form a unique fingerprint.

Cite this